HDAC9 and Miyoshi myopathy: Based on this model, Arhoma et al. [58] reported the effects of Tumour Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) and HDAC inhibitors in six human MM cell lines and primary plasma cell leukemia.